Diagnostics and therapeutics for macular...

Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C435S007100, C435S007400, C435S007800, C530S350000, C530S380000

Reexamination Certificate

active

07351524

ABSTRACT:
The invention relates to methods for treating, preventing and diagnosing macular degeneration-related disorders.

REFERENCES:
patent: 3654090 (1972-04-01), Schuurs et al.
patent: 5472939 (1995-12-01), Fearon et al.
patent: 5681571 (1997-10-01), Holmgren et al.
patent: 5686598 (1997-11-01), North et al.
patent: 5705380 (1998-01-01), North et al.
patent: 5773573 (1998-06-01), Holms
patent: 5843449 (1998-12-01), Boots et al.
patent: 5951984 (1999-09-01), Kaneko et al.
patent: 6087120 (2000-07-01), Van Oeveren et al.
patent: 6103235 (2000-08-01), Neville et al.
patent: 6153203 (2000-11-01), Holmgren et al.
patent: 7011952 (2006-03-01), Hageman et al.
patent: 7108982 (2006-09-01), Hageman
patent: 2002/0015957 (2002-02-01), Hageman et al.
patent: 2002/0102581 (2002-08-01), Hageman et al.
patent: 2003/0017501 (2003-01-01), Hageman et al.
patent: 2005/0119536 (2005-06-01), Hageman
patent: 2005/0287601 (2005-12-01), Hageman et al.
patent: 2006/0263819 (2006-11-01), Hageman et al.
patent: WO 90/15152 (1990-12-01), None
patent: WO 95/17673 (1995-06-01), None
patent: WO 97/38004 (1997-10-01), None
patent: WO 00/52479 (2000-09-01), None
patent: WO 01/84149 (2001-11-01), None
Roitt, I. et al. Immunology [1985 ], Roitt et al. editors. C.V. Mosby Company, St. Louis. pp. 7.1-7.14.
Paul W. E., editor. Fundamental Immunology, 2nd edition. Raven Press, New York. [1989 ]p. 681.
Abraha, A. and Luzio, J.; “Inhibition of the formation of the complement membrane-attack complex by a monoclonal antibody to the complement component C8aSubunit”,Biochem J, 1989, pp. 933-936; 264, Great Britain.
Akiyama, H. et al; “Inflammation and Alzheimer's disease”;Neurobioy of Aging 21; May-Jun. 2000; pp. 383-421; vol. 21, No. 3.
Allikmets, R. et al; “Mutation of the Stargardt Disease Gene (ABCR) in Age-Related Macular Degeneration”,Science, Sep. 19, 1997; pp. 1805-1807, vol. 277.
Auda, G. et al; “Measurement of complement activation products in patients with chronic rheumatic disease”,Rheumatology International; 1990, 10(5):pp. 185-189, Springer-Verlag.
Baatrup, G. et al; “Effects of coagulation temperature on measurements of complement function in serum samples from patients with systemic lupus erythematosus”,Annuals of Rheumatic Disease; 1992, 51(7):892-897.
Bachinsky, D. et al; “Detection of Two Forms of GP330”,American Journal of Pathology.; Aug. 1993, pp. 598-611, vol. 143, No. 2.
Bhakdi, S. & Tranum-Jensen, J.; “Membrane Damage by Complement”,Biochimica et Biophysica Acta; 1983, pp. 343-372; 737, Elsevier Science Publishers B.V.
Bora, N.S. et al.; “Differential expression of the complement regulatory proteins in the human eye”,Investigative Ophthalmology & Visual Science; Dec. 1993, pp. 3579-3584, vol. 34, No. 13.
Braley-Mullen; “Activation of Distinct Subsets of T Suppressor Cells with Type III Pheumococcal Polysaccharide Coupled to Syngeneic Spleen Cells”,Immunological Tolerance To Self and Non-Self, Annals of New York Academy of Science, 1982, pp. 156-166, vol. 392.
Burger, R. et al; “The C Terminus of the Anaphylatoxin C3a Generated Upon Complement Activation Represents a Neoantigenic Determinant with Diagnostic Potential”,Journal of Immunology, Jul. 15, 1988; pp. 553-558, vol. 141, No. 2, Printed in the U.S.A.
Buyon, J. et al.; “Assessment of Disease Activity and Impending Flare in Patients with Systemic Lupus Erythematosus”,Arthritis and Rheumatism; Sep. 1992, pp. 1028-1037, vol. 35, No. 9.
Campbell, R. et al; “An Anion Binding Study of Vanadyl(IV) Human Serotransferrin”,Journal of Biological Chemistry; 1977, pp. 5996-6001, vol. 252, No. 17, Printed in the U.S.A.
Caraher, E.M. et al; “Evidence for enhanced rates of complement activation in serum from patients with newly diagnosed insulin-dependent diabetes mellittus exposed to rat islet cells and complement-dependent induction of islet cell apoptosis.”,Journal of Endocrinology; 1999, pp. 143-153, vol. 162, No. 1, Printed in Great Britain.
Chenoweth, D. et al; “Complement Activation During Cardiopulmonary Bypass”,New England Journal of Medicine; Feb. 26, 1981; pp. 497-502, vol. 304, No. 9, Printed in the U.S.A.
Chain, B. et al; “Improvement of the in vitro T cell proliferation assay by a modified method that separates the antigen recognition and IL-2-dependent steps.”.Journal of Immunological Methods; 1987, pp. 221-228, vol. 99.
Debrock, S. and Declerck, P.; “Characterization of common neoantigenic epitopes generated in plasminogen activator inhibitor-1 after cleavage of the reactive center loop or after complex formation with various serin proteinases.”,FEBS Letters; 1995, pp. 243-246, vol. 376.
Delori, F. and Ben-Sira, I.; “Excitation and emission spectra of fluorescein dye in the human ocular fundus,”,Investigative Ophthalmology; Jun. 1975, pp. 487-492, vol. 14, No. 8.
Delori, F. et al; “In Vivo Fluorescence of the Ocular Fundus Exhibits Retinal Pigment Epithelium Lipofuscin Characteristics”,Investigative Ophthalmology&Visual Science; Mar. 1995, pp. 718-729, vol. 38, No. 3.
Detrick, B. et al.; “Class II Antigen Expression and Gamma Interferon Modulation of Monocytes and Retinal Pigment Epithelial Cells from Patients with Retinitis Pigmentosa”,Clinical Immunology and Immunopathology, Aug. 1985, pp. 201-211, vol. 36, No. 2, San Diego, CA, U.S.A.
Edwards, A. et al; “Malattia Leventinese: Refinement of the Genetic Locus and Phenotypic Variability in Autosomal Dominant Macular Drusen”,American Journal of Ophthalmology; Sep. 1998, pp. 417-424, vol. 126, Elsevier Science Inc.
Egerton, M. et al; “Identification of Ezrin as an 81-kDa Tyrosin-Phosphorylated Protein in T Cells”,The Journal of Immunology, Sep. 15, 1992; pp. 1847-1852, vol. 149, No. 6, Printed in the U.S.A.
Enk, C. et al; “A Standardized Human T-lymphocyte Proliferation Assay for Detecting Soluble Accessory Factors From Monocytes”, Acta Pathol Microbiol Immunol Scand [C], 1984, pp. 93-100, vol. 92, No. 2.
Epstein, G.A. and Rabb, M.F.; “Adult vitelliform macular degeneration: diagnosis and natural history”;British Journal of Ophthalmology, 1980, pp. 733-40, vol. 64.
Felbor, U. et al; “Adult vitelliform Macular Dystrophy Is Frequently Associated With Mutations in the Peripherin/RDS Gene”,Human Mutation; 1997, pp. 301-309, vol. 10.
Felbor, U. et al; “Autosomal Recessive Sorsby Fundus Dystrophy Revisited: Molecular Evidence for Dominant Inheritance”,American Journal of Human Genetics; 1997, pp. 57-62, vol. 60.
Fitzgibbon, J. et al; “Localisation of the human blue cone pigment gene to chromosome band 7q31.3-32”,Human Genetics; 1994, pp. 79-80, vol. 93.
Forstrom, J.W. et al; Immunization to a syngeneic sarcoma by a monoclonal auto-anti-idiotypic antibody,Nature; Jun. 16, 1983; pp. 627-629, vol. 303.
Giltay, R. et al; “Sequence, Recombinant Expression and Tissue Localization of Two Novel Extracellular Matrix Proteins,fibulin-3 andfibulin-4”, Matrix Biol, Oct. 1999, pp. 469-480, vol. 18, No. 5.
Gorski, J.; “Quantitation of Human Complement Fragment C4ai in Physiological Fluids by Competitive Inhibition Radioimmune Assay”,Journal of Immunological Methods; 1981, pp. 61-73, vol. 47, Elsevier/North-Holland Biomedical Press.
Goslings W., et al.; “Membrane-Bound Regulators of Complement Activation in Uveal Melanomas. CD46, CD55, and CD59 in Uveal Melanomas”;Investigative Ophthalmology&Visual Science, Aug. 1996, pp. 1884-1891, vol. 37, No. 9.
Green, W.R.; “Histopathology of age-related macular degeneration”,Molecular Vision, Nov. 1999, vol. 5, No. 27.
Griesinger, I.B. et al; Macular Degeneration with Highly Variable Phenotype Localized to Chromosome 6q.American Journal of Human Genetics; 63:A30; 1998.
Gurne, D. et al; “Antiretinal Antibodies in Serum of Patients with Age-relat

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Diagnostics and therapeutics for macular... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Diagnostics and therapeutics for macular..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diagnostics and therapeutics for macular... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-2743835

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.